← FDA DRUG APPROVALS

FDA ANDA · ANDA077767

GALANTAMINE HYDROBROMIDE

Sponsor: WATSON LABS

APPLICATION
ANDA077767
TYPE
ANDA
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
None (Tentative Approval)

Products

GALANTAMINE HYDROBROMIDENone (Tentative Approval)
GALANTAMINE HYDROBROMIDE EQ 12MG BASE · TABLET · ORAL
GALANTAMINE HYDROBROMIDENone (Tentative Approval)
GALANTAMINE HYDROBROMIDE EQ 4MG BASE · TABLET · ORAL
GALANTAMINE HYDROBROMIDENone (Tentative Approval)
GALANTAMINE HYDROBROMIDE EQ 8MG BASE · TABLET · ORAL

Approval history

2007-03-30OriginalTA
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →